Ken-ichiro Kosai（Executive Chairman, Founder & CSO, Ph.D., M.D.）

• Professor, Dept. of Gene Therapy & Regenerative Medicine, Graduate School of Medical & Dental Sciences, Kagoshima University
• Pioneered development of next-generation m-CRA (conditionally-replicating adenovirus specifically targeting tumors with multiple factors) platform technology as a prospective new cancer therapy in the globally-anticipated field of oncolytic viruses (OVs).
• In a Phase I study, the first-generation Surv.m-CRA-1 yielded globally superior results to those of competing technologies, and a Phase II study is currently underway with an eye to gaining regulatory approval. The second-generation Surv.m-CRA-2 is also under development

Masaki Yamada（Representative Director, President, Ph.D., M.B.A.）

• More than 35 years of experience in pharmaceutical R&D
• Previously Head of Pharmacology Research Lab & Manager of the Sohyaku (Innovative Research) Strategy & Planning Dept., Sohyaku Innovative Research Div. At Mitsubishi Tanabe Pharma, and former President of Tanabe Research Labs, U.S.A.
• Highly-experienced in R&D strategy development & project management and in promoting open innovation

Yoshihiro Takano（Executive Director & CFO)

• C.P.A.
• Successfully listed a healthcare tech venture on the Tokyo Stock Exchange Growth Market as its CFO, and has wide-ranging business experience with a focus on corporate planning & business development for banks, general trading companies, major retailers and other listed corporations

Matsugaki Mikio （Corporate Auditor）

• Well versed in internal auditing, finance & accounting, with more than 30 years experience at a government-affiliated bank
• Practical experience in listing a bioventure as Corporate auditor

Muneo Takatani（Independent Corporate Auditor）

• Doctor of Pharmacology, Visiting Professor at Kagoshima University
• Garnered extensive experience from basic research to business development & management while employed at Takeda Pharmaceutical, and served as Specially Appointed Professor at Kyoto University
• Also acts as director of a bioventure company originating from Kyoto University

Kiichiro Kawada（Independent Corporate Auditor）US C.P.A. & M.B.A. 

• Mr. Kawada is a US C.P.A., holds a US M.B.A. degree, and spent 14 years in the U.S., where he worked at Deloitte Touche LLP as a client service representative.
• After returning to Japan, he worked for Deloitte Tohmatsu FAS and a government revitalization fund as a M&A advisor and in revitalization operations.
• In 2009, he became CFO of a listed drug discovery venture (RaQualia Pharma Inc.).
• Currently, he is involved in mentoring promising Japanese bioventures nearing IPO and advising startup ventures.

Hiroki Narita（Independent Director）

Norihide Hayakawa（Independent Director）

Tomokatsu Hongo（Independent Director）

Akira Kawai (Scientific Advisor) M.D., Ph.D.

• M.D., Ph.D., Okayama University Graduate School of Medicine. An orthopaedic surgeon with more than 30 years of clinical and research experience in bone and soft tissue tumors (sarcomas)
• Conducted research as a Research Fellow at Memorial Sloan Kettering Cancer Center in New York
• After serving as Lecturer in the Department of Orthopaedic Surgery at Okayama University Hospital and Chief of Orthopaedic Surgery at the National Cancer Center Hospital, held key positions including Director of the Rare Cancer Center, National Cancer Center Japan, and Chief of the Department of Musculoskeletal Oncology and Rehabilitation Medicine, National Cancer Center Hospital
• As a leading expert in rare cancers, has played a central role in building Japan’s clinical and research framework for rare cancers
• Currently affiliated with the Rare Cancer Center, National Cancer Center Japan, and, since 2026, also with the Department of Rehabilitation Medicine, Kanagawa Cancer Center